Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Refractory Behcet's Syndrome
NCT07080346Phase 2Completed
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of upadacitinib in Behcet syndrome. Started Jan 2024; status: completed.
02
Drugs
upadacitinib
03
Conditions
Behcet syndrome
Beyond the preview
Go deeper on NCT07080346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07080346.